Duo secure primary positions on innovative $175m pharmaceuticals joint venture
December 01, 2004 at 07:03 PM
1 minute read
The original version of this story was published on Legalweek
Bird & Bird and Morrison & Foerster (MoFo) have won lead roles acting on a major joint venture between AstraZeneca and Cambridge Antibody Technology (CAT), in a move that hands Bird & Bird its first major instruction for the FTSE 100 pharmaceuticals giant.
The agreement will see the two companies fund a minimum of 25 antibody development programmes with at least $175m (£93.5m) invested by the alliance partners.
Presented by BigVoodoo
Celebrating achievement, excellence, and innovation in the legal profession in the UK.
Legalweek New York explores Business and Regulatory Trends, Technology and Talent drivers impacting law firms.
Women, Influence & Power in Law Awards honors women lawyers who have made a remarkable difference in the legal profession.
Smith Mazure, PC, is a highly respected results-oriented law firm serving insurance carriers and self-insured corporations for 50 years. We ...
Meyer, Suozzi, English & Klein, P.C. is seeking a Junior-level Litigation Associate licensed to practice in NY with 2-4 years experienc...
Please note: Our client is hiring multiple attorneys for their offices in Angleton, Pearland, League City, and Friendswood, TX. While this i...
